E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Follicular, CD20-Positive B-Cell Non-Hodgkin's Lymphoma Linfoma Non-Hodgking folicular con céluas B CD20 positivas |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10029593 |
E.1.2 | Term | Non-Hodgkin's lymphoma NOS |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety and tolerability of Apomab when combined with rituximab for the treatment of patients with relapsed follicular, CD20-positive B-cell non-Hodgkin’s lymphoma (NHL). To make a preliminary assessment of the efficacy of Apomab when combined with rituximab for the treatment of patients with relapsed follicular, CD20-positive B-cell NHL, as measured byobjective response rate.
|
|
E.2.2 | Secondary objectives of the trial |
To make a preliminary assessment of the efficacy of Apomab when combined with rituximab for the treatment of patients with relapsed follicular, CD20-positive B-cell NHL, as measured by progression-free survival, duration of response, and overall survival. To evaluate the serum pharmacokinetics of Apomab and rituximab when combined for the treatment of patients with relapsed follicular, CD20-positive B-cell NHL. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
>Signed Informed Consent Form > Age ≥18 years >Diagnosis of follicular, CD20-positive B-cell NHL classified as Grade 1, 2, or 3a according to the WHO classification of malignant lymphomas >Progression of disease after an objective response (CR/CRu or PR) or SD lasting 6 months following completion of the most recent rituximab-containing regimen >A rituximab-containing regimen is defined as rituximab as a single agent during induction and/or maintenance, or in combination with other agents. >Measurable disease (according to modified IWG Criteria; see Appendix B) ECOG performance status of 0 or 1 (see Appendix D) >Life expectancy of 3 months >Willingness and capability to be accessible for follow-up until study termination or death >For patients of reproductive potential (both males and females), use of a reliable means of contraception (e.g., contraceptive pill, intrauterine device [IUD], barrier methods) throughout the trial and for 1 year following their last exposure to study treatment
|
|
E.4 | Principal exclusion criteria |
>Grade 3b follicular lymphoma (according to the WHO classification) or histologic transformation from follicular lymphoma to aggressive lymphoma >Prior radiotherapy to a lesion(s) that will be used to assess response unless that lesion(s) shows clear evidence of lymphoma progression at baseline (i.e., ≥50% increase in the product of the longest perpendicular diameters of the lesion [greatest transverse diameter perpendicular diameter] when compared with the nadir of lesion dimensions following radiotherapy and 1.5 cm in the greatest transverse diameter) >Radiotherapy to a peripheral lesion within 14 days prior to Cycle 1, Day 1 or radiotherapy to a thoracic, abdominal, or pelvic field within 28 days prior to Cycle 1, Day 1 >Prior radio-immunotherapy, including radiolabeled antibodies >Concurrent systemic corticosteroid therapy (except low-dose corticosteroid therapy used to treat an illness other than lymphoma) >Other invasive malignancies within 5 years prior to Cycle 1, Day 1 (other than basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix treated with curative intent) >History or evidence on physical examination of central nervous system (CNS) disease (e.g., primary brain tumor, CNS lymphoma, seizures not controlled with standard medical therapy, any brain metastases, or history of stroke) >Prior treatment with agonistic DR4 or DR5 antibodies or Apo2L/TRAIL >General Medical Concerns >Current or recent (within the 28 days prior to Cycle 1, Day 1) participation in another experimental drug study >Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, myocardial infarction within 1 year prior to Cycle 1, Day 1, unstable angina), New York Heart Association (NYHA; see Appendix E) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication within 1 year prior to Cycle1, Day 1, or Grade II or greater peripheral vascular disease (see Appendix F) at study entry >Active infection requiring parenteral antibiotics on Cycle 1, Day 1 Protocol: Apomab—Genentech, >Major surgical procedure (excluding lymph node biopsy) or significant traumatic injury within 28 days prior to Cycle 1, Day 1, or anticipation of need for major surgical procedure during the course of the study >Pregnancy (positive pregnancy test) or breast feeding >Serious, non-healing wound, ulcer, or bone fracture Laboratory values ANC 1500/L (may not be treated with G-CSF to maintain or exceed this level) Platelet count 75,000/L Total bilirubin1.6 mg/dL AST or ALT 2.5 the upper limit of normal (ULN) Serum creatinine 2.0 mg/dL or measured creatinine clearance ≤50 mL/min Hemoglobin 9 g/dL (may not be transfused or treated with erythropoietin to maintain or exceed this level) >Known human immunodeficiency virus (HIV) infection, seropositivity for hepatitis B surface antigen (HBsAg), hepatitis B IgG or IgM core antibody, or hepatitis C virus (HCV) antibody >History of other disease, metabolic dysfunction, physical finding, or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the patient at high risk from treatment complications
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Objective response (defined as a PR or CR/CRu, occurring within 8 months post-randomization), as determined by the IRF using modified IWG Criteria
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Information not present in EudraCT |
E.7.4 | Therapeutic use (Phase IV) | Information not present in EudraCT |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Information not present in EudraCT |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 17 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |